Ocuphire Pharma Inc

NASDAQ:OCUP   4:00:00 PM EDT
3.23
+0.15 (+4.87%)
7:38:55 PM EDT: $3.42 +0.19 (+5.88%)
Earnings Announcements

Ocuphire Pharma Announces Financial Results For Q3 2022

Published: 11/04/2022 20:38 GMT
Ocuphire Pharma Inc (OCUP) - Ocuphire Pharma Announces Financial Results for Third Quarter 2022 and Provides Corporate Update.
Topline Data From Zeta-1 Phase 2b Trial of Oral Apx3330 Expected in Early 2023.
NDA Submission for Nyxol for Rm and Initiation of Vega-2 on Track for Q4 2022.
Qtrly Loss per Share $0.22.
Q3 Earnings per Share View $-0.29 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $28.06 Million
Adjusted EPS is expected to be $0.72

Next Quarter Revenue Guidance is expected to be $3.68 Million
Next Quarter EPS Guidance is expected to be -$0.14

More details on our Analysts Page.